

Nausea: Nausea is the most common adverse reaction (up to 30% incidence rate).Instruct patients to discontinue CHANTIX and contact a healthcare provider immediately at first appearance of skin rash with mucosal lesions. Serious skin reactions: Rare, potentially life-threatening skin reactions have been reported.Instruct patients to discontinue CHANTIX and immediately seek medical care if symptoms occur. Angioedema and hypersensitivity reactions: Such reactions, including angioedema, infrequently life threatening, have been reported.Instruct patients to notify their health care providers of new or worsening cardiovascular symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction or stroke. In both the clinical trial and meta-analysis, all-cause and cardiovascular mortality was lower in patients treated with CHANTIX. These events occurred primarily in patients with known cardiovascular disease. Cardiovascular events: A meta-analysis of 15 clinical trials, including a trial in patients with stable cardiovascular disease, demonstrated that while cardiovascular events were infrequent overall, some were reported more frequently in patients treated with CHANTIX.Instruct patients to use caution driving or operating machinery until they know how CHANTIX may affect them.


